A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
Stopped Company decided not to pursue the development of this drug in this patient population at this time
Conditions
- Advanced Hepatocellular Carcinoma (HCC)
Interventions
- DRUG: OSI-906
- DRUG: Placebo
Sponsor
Astellas Pharma Inc